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Abstract
Background & Aims: It is not known if specific characteristics of medication are associated
with type of drug-induced liver injury (DILI) or outcome. We examined the relationships among
select characteristics of medications and DILI phenotype and outcome.
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Methods: We analyzed 383 cases of DILI caused by a single orally administered prescription
agent from the DILI Network Prospective Study with causalities of definite, highly likely, or
probable. Relationship of daily dosage (≥ 50 mg vs. ≤ 49 mg), preponderance of hepatic
metabolism (≥50% vs <50%), or Biopharmaceutics Drug Disposition Classification System
(BDDCS) class (1–4, based on solubility and metabolism of the drug) were compared with clinical
characteristics and outcomes.
Results: Compared to cases of DILI in the <50 mg/day group, those associated with daily
dosages ≥50 mg had shorter latency (median 38 days vs 56 days; P=.03) and a different
biochemical pattern of liver injury (P=.04); no differences in pattern of injury, recovery, severity,
or outcome were observed. Patients with DILI caused by medications with or without
preponderant hepatic metabolism did not differ in clinical characteristics or outcomes. Compared
to other classes of BDDCS, DILI caused by BDDCS class 1 medications had significantly longer
latency (P<.001) and greater proportion of hepatocellular injury (P=.001). However, peak liver
biochemical values and patients’ time to recovery, disease severity, and outcomes did not differ
among the 4 BDDCS classes.
Conclusions: Characteristics of medications (dosage, hepatic metabolism, and solubility) are
associated with features of DILI such as latency and pattern of liver injury, but not with recovery,
severity, or outcome.
Keywords
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INTRODUCTION
Idiosyncratic drug-induced liver injury (DILI) likely occurs due to complex interplay among
host factors, environmental variables and the nature of the offending agent.1 Research
efforts over the last decade have therefore focused primarily on the understanding of the
genetic factors that increase an individual’s susceptibility to DILI.2, 3 However, medication
characteristics such as daily dose administered and their metabolism profile are starting to
emerge as potential risk factors for DILI.4-7
It was initially pointed out by J. Uetrecht that drugs given at a daily dose of 10 mg or less
are rarely if ever associated with a high incidence of DILI and majority of the drugs that
were either withdrawn from the market or received a black box warning due to
hepatotoxicity were prescribed at daily doses greater than 50 mg.8 Lammert et al. reported a
statistically significant relationship between daily dose of oral medicines and reports of liver
failure, liver transplantation and death due to DILI.6 Lammert et al. also reported that
compounds with >50% hepatic metabolism had significantly higher frequency of ALT >3X
ULN, liver failure and fatal DILI.4 Recently, Chen et al. suggested a combined effect of
daily dosage of >100 mg and high lipophilicity on the risk of DILI among medications
approved by the Food and Drug Administration. 5
Drugs with higher lipophilicity resulting in increased permeability and uptake by
hepatocytes may undergo greater biotransformation leading to toxic metabolites and
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heightened susceptibility to DILI.7, 9 Conversely, drugs with low lipophilicity have low
permeability, undergo less hepatic metabolism and may be at lower risk for causing DILI as
they are primarily eliminated unchanged into the urine and bile.7, 9 However, some drugs
(cefadroxil, cephradine, levofloxacin, loracerbef, ofloxacin, sotalol and pregabalin)
classified as having low permeability exhibit high absorption ≥90% due to presence of
intestinal drug transporters.10 By evaluating metabolism, not permeability or lipophilicity,
drugs can be categorized into four classes according to their solubility and metabolism using
the Biopharmaceutics Drug Disposition Classification System (BDDCS) classification:
Class 1 (High solubility- Extensive metabolism), Class 2 (Low solubility- Extensive
metabolism), Class 3 (High Solubility- Poor metabolism), and Class 4 (Low solubility –
Poor Metabolism).11-13 The current study investigated the relationship between DILI
phenotypic characteristics and select drug properties such as a) daily dosage: ≥50 mg b)
predominant hepatic metabolism (>50%) and c) BDDCS classes 1-4.
METHODS
We extracted data from the U.S. DILIN prospective study database with the following
eligibility criteria: (a) Cases that have been causality adjudicated with a DILIN causality
score probable or higher as described previously16, 17 and (b) DILI caused by single oral
prescription agent taken daily. A DILIN severity score was assigned according to a
previously published scale from 1 (mild with serum total bilirubin <2.5 mg/dL) to 5 (death
or liver transplantation).14, 15 Information regarding the drug dosage administered to the
patient was extracted from the DILIN database (DILIMED). Drugs were categorized based
on daily dosage into those with and without appreciable hepatic metabolism based on
information within drug’s approved package insert, DrugBank (www.drugbank.ca) or
DailyMed (dailymed.nlm.nih.gov). BDDCS classification of the drugs was obtained from
previously published literature.11 By evaluating metabolism, not permeability, BDDCS is
not subject to variability due to transporter effects.11, 12 Demographic, biochemical and
clinical outcomes were extracted and analyses were performed on the following variables (a)
latency (time from drug exposure to DILI onset), (b) time to peak values for total bilirubin,
(c) time to recovery (peak to 50% reduction in total bilirubin), (d) DILIN severity score, and
(e) outcomes (hospitalization, liver related death and transplant).
The data analyses were performed at the Duke Clinical Research Institute, the data
coordinating center of the DILIN. SAS v 9.2 was used to aid all analyses. Continuous
variables were summarized with mean and standard deviation or median and interquartile
range (IQR). Categorical data were expressed as counts and proportions. Fisher’s exact test
was used to analyze differences between groups for the categorical data and differences
between groups for continuous variables were assessed with a non-parametric test
(Wilcoxon test for two groups or Kruskal–Wallis one-way analysis of variance for more
than two groups). P-values less than 0.05 were considered statistically significant. There was
no adjustment made for multiplicity of comparisons. The authors had access to the study
data and have reviewed and approved the final manuscript.
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RESULTS
A total of 1083 DILI subjects enrolled up to March 2012 were screened to identify 383 cases
that met the eligibility criteria (Fig 1). A total of 107 drugs were responsible for these DILI
episodes. We could not obtain the details of hepatic metabolism on 3 (febuxostat,
investigational drug, ranitidine) and the specifics of BDDCS in 8 drugs (benzonatate,
deferasirox, flavocoxid, investigational drug, phentermine, regorafenib, salsalate, and
thiamazole). The mean age of the patients in the study cohort was 50 ± 18 years with 63%
women and 79% Caucasian.
Relationship between drug dose and DILI phenotype and outcomes
Episodes of DILI due to drugs with daily dosage ≥ 50 mg had significantly shorter latency
period as compared to those who received ≤ 49 mg per day [38 (20-96) vs.56 (30-208) days,
P=.03]. The pattern of liver injury (Cholestatic/Mixed/Hepatocellular) at onset was also
significantly different between two dosage groups (P=.04), with a greater proportion of
cholestatic liver injury in ≤ 49 mg per day. However, no other significant differences were
noted between the groups with regard to peak values of liver biochemistries, time to peak,
and time to recovery (Table 1). The DILIN severity scores were not significantly different
based on dose classification (P=.3). Similarly, clinical outcomes such as hospitalization rate,
liver-related death and liver transplantation rate were not different between two groups
(Table 1).
Relationship between drug metabolism and DILI phenotype and outcomes
In the current cohort, a higher number of cases had DILI from drugs that underwent
significant hepatic metabolism (n=305) compared to those without hepatic metabolism
(n=71). The two groups otherwise did not differ with regard to variables such as latency,
pattern of liver injury, time to peak, and time to recovery. The DILIN severity scores were
not significantly different based on hepatic metabolism classification (P=.3). Outcomes such
as hospitalization rate (55% vs. 44%, P=.3), liver-related death (2% vs. 5.6%, P=.7) and
liver transplant (3.3% vs. 1.4%, P=.7) were not different between two groups (Table 1).
Relationship of BDDCS classification with DILI phenotype and outcomes
A total of 99 drugs belonging to BDDCS Classes 1 through 4 were responsible for these
DILI episodes (Table 2). The distribution of cases belonging to each BDDCS group was
different with underrepresentation of DILI cases caused by BDDCS Class 4 agents. Four
compounds (ciprofloxacin, nitrofurantoin, cefdinir and levonorgestrel//ethinylestradiol)
accounted for all cases of DILI belonging to BDDCS Class 4 (Table 2). DILI cases from
drugs belonging to Class 4 differed from other groups in having a significantly lower
percentage of jaundiced patients (P<0.001), absolute eosinophilia >500/uL (P=.008) with
lower peak ALT (p=0.001) and AST (P <0.001).The groups differed significantly with
regard to latency period with Class 1 having the longest latency period (P <0.001) (Table 1).
The pattern of liver injury at onset was significantly different between the groups (P <0.001)
with Class 1 having the highest proportion of HC pattern (76%). However, no significant
differences were noted between the groups with regard to time to peak total bilirubin and
time to recovery. Hospitalization rate was significantly different among the groups (P=.01)
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with Class 4 having the lowest rates at 45% (Table 1). However, outcomes such as liver
related death (P=.1) and transplantation rate (P=.3) were not different (Table 1).
DISCUSSION
Although prior studies have suggested a relationship between drug characteristics and their
propensity to cause DILI, data regarding drug characteristics and DILI phenotype are
lacking. In the current study, we leveraged the unique features of DILIN database to
examine the relationships among drug characteristics and DILI phenotype and outcomes.
The current observations of shorter latency with daily dosage of ≥ 50 mg and a higher peak
ALT with drugs that undergo hepatic metabolism demonstrate the importance of the
intrinsic drug properties as a potential factor for the development of a DILI event. These
findings also suggest that a threshold level of parent drug, metabolite, and / or adducts is a
prerequisite for the DILI event. However, lack of any significant differences in the clinical
outcomes supports the current understanding that the mechanism of injury and subsequent
recovery may be predominantly mediated by the host immune response or host susceptibility
due to genetic or acquired inability to detoxify hepatotoxic drug intermediates.1, 16, 17
Further studies are needed to examine how these properties influence mechanisms involved
in DILI such as CYP bioactivation reactions, covalent binding, or mitochondrial
toxicity.18, 19
Our examination of the relationship among drug properties such as aqueous solubility /
gastrointestinal permeability using BDDCS classification20, 21 and DILI phenotype or
outcomes led to some novel observations. First, drugs belonging to Class 4 (cefdinir,
ciprofloxacin, nitrofurantoin, and levonorgestrel with ethinylestradiol) were incriminated in
lower percentage of DILI patients, possibly because BDDCS class 4 drugs are
underrepresented in orally approved drugs. These BDDCS class 4 drugs were associated
with a significantly lower peak serum aminotransferase levels presumably due to their low
permeability and solubility resulting in reduced uptake and lower hepatic biotransformation.
A detailed review of these cases showed instances where prolonged exposure of the drug
occurred (in some cases of nitrofurantoin exposure occurred for several years) before the
DILI episode occurred. Second, the current study identified 81% of the drugs causing DILI
episodes as undergoing extensive hepatic metabolism, suggesting that a reactive metabolite
intermediate, rather that the native drug may be responsible for the development of a DILI
event, possibly through the formation of adduct complexes, acting as neoantigens.
Autoimmune DILI is often associated with presence of serum autoantibodies directed
against hepatic cytochrome P450s or other hepatic proteins.22 The covalent binding of the
drug or reactive metabolite to liver microsomal proteins results in formation of a neoantigen
with subsequent injury from immune response.23, 24 It is thus plausible that drugs that
belong to BDCSS class 1 and 2 (Extensive metabolism) may be at increased risk of causing
autoimmune DILI. In the current study, we observed that several drugs that have previously
been implicated to cause autoimmune DILI22 belonged to BDCSS Class 1 (hydralazine,
minocycline, propylthiouracil, methylphenidate and diclofenac) and 2 (atorvastatin,
imatinib, fenofibrate and terbinafine) (Table 2). However, two drugs with definite
association with autoimmune DILI i.e., methyldopa (BDCSS Class 3) and nitrofurantoin
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(BDCSS Class 4) diverge from this pattern suggesting additional role of host related factors
as being critical for a DILI event.
Lastly, the unique strengths of the DILIN cohort such as the ability to examine DILI cases
with strong causality (1, 2, or 3) and availability of prospectively captured DILI phenotype
and outcomes allowed us to perform the current study. The pitfalls common in the literature
such as DILI case definition and causality adjudication are minimized in the DILIN
prospective study because of its study design. 14, 15, 25 The current study failed to find any
significant differences in clinic outcomes based on daily dosage in contrast to the earlier
study by Lammert et al. who evaluated the Swedish registry. It is likely that these
differences could be related to the DILIN registry prospective protocol and the current study
design that included only DILI cases from single agent and with causality limited to the
scores of 1, 2 or 3. It is also possible that lack of relationship between drug metabolism as
well as of BDDCS classification with clinical outcomes might be due to lack of adequate
sample size.
In summary, drug characteristics such as daily dosage ≥50 mg and BDDCS Class 1 are
related to select aspects of DILI phenotype. However, the severity of liver disease and
outcomes are not associated with drug characteristics. We speculate that DILI outcomes may
be more related to host response rather than drug characteristics.
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Figure 1.
Flowchart describing the selection of the study population. A total of 1083 subjects with
drug induced liver injury (DILI) were enrolled up to March 2012. Among these, 631
subjects had DILI from a single drug. After causality adjudication, there were 412 subjects
with adjudication status of definite, highly likely, and probable (1, 2 or 3). An additional 29
cases were excluded due to unknown dosage, drug start/stop date or mode of administration.
The final study cohort consisted of 383 DILI cases resulting from 107 different drugs
satisfied the study inclusion criteria: (a) DILI occurring from a single agent, (b)
administered orally, (c) known daily dosage, and (d) causality of 1, 2 or 3.
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Table 1
Relationship between drug characteristics and the DILI phenotype and outcomes (N=383).
Latency
(days)
Pattern of liver
injury at
onset (C/M/HC,
%)
Time to Peak
(days)
Time to
Recovery
(days)
Hospitalization
(%)
Liver
related
Death (%)
Transplant
(%)
Daily dose
≥ 50 mg (n =324) 38 (20-96) 21/25/54 8 (2-15) 31 (13-51) 52 2.8 3.4
≤49 mg (n=53) 56 (30-208) 32/11/57 10 (4-22) 36 (12-70) 62 1.9 0
(p=0.03) (p=0.040) (p=0.1) (p=0.3) (p=0.2) (p=1.0) (p=0.4)
Hepatic Metabolism
Yes (n=305) 42 (25-100) 23/24/53 8 (2-16) 33 (13-56) 55 2.0 3.3
No (n=71) 34 (16-101) 23/21/56 7 (2-17) 31 (12-45) 47 5.6 1.4
(p=0.3) (p=0.9) (p=0.9) (p=0.3) (p=0.2) (p=0.1) (p=0.7)
Biopharmaceutics Drug Disposition Class
Class 1 (n=118) 81 (43-214) 12/12/76 7 (2-14) 27 (12-44) 53 2.5 5.1
Class 2 (n=96) 35 (43-214) 25/29/46 10 (3-23) 31 (10-55) 68 2.1 1.0
Class 3 (n=112) 28 (16-44) 32/29/39 7 (1-13) 38 (17-53) 46 0.9 1.8
Class 4 (n=38) 38 (15-568) 26/24/50 11 (3-22) 25 (7-49) 45 7.9 2.6
(p<0.001) (p<0.001) (p=0.1) (p=0.1) (p=0.01) (p=0.1) (p=0.3)
All values are expressed as median (IQR) unless otherwise expressed. R ratio was calculated by dividing the ALT by the ALP from initial blood
test, using multiples of the ULN for both values. R ≤ 2 Cholestatic (C) pattern of DILI, 2 < R < 5 Mixed (M) pattern of DILI, or R > 5:
Hepatocellular (HC) pattern of DILI.
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Table 2
List of drugs implicated in the DILI episode. Drugs arranged as per Biopharmaceutics Drug Disposition
Classification System (BDDCS) class. A total of 99 drugs with BDDCS class of 1, 2, 3 or 4 were responsible
for 372 cases of DILI. Drugs that are underlined have been associated with autoimmune DILI phenotype.
Class 1 Class 2 Class 3 Class 4
(High solubility – Extensive
metabolism)
(n=118)
(Low solubility – Extensive
metabolism)
(n=99)
(High solubility – Poor
metabolism)
(n=115)
(Low solubility – Poor
metabolism)
(n=40)
ALFUZOSIN (n=1) ACITRETIN (n=3) AMOXICILLIN (n=6) CEFDINIR (n=1)
ALISKIREN (n=1) ALLOPURINOL (n=2) AMOXICILLIN CIPROFLOXACIN (n=11)
ATOMOXETINE (n=3) AMIODARONE (n=4) W/CLAVULANIC ACID LEVONORGESTREL
AZATHIOPRINE (n=4) ATORVASTATIN (n=4) (n=61) W/ETHINYLESTRADIOL
BUPROPION (n=3) BOSENTAN (n=1) ATENOLOL (n=1) (n=1)
CLINDAMYCIN (n=1) CARBAMAZEPINE (n=2) AZITHROMYCIN (n=4) NITROFURANTOIN
CYCLOPHOSPHAMIDE (n=2) CELECOXIB (n=2) BENAZEPRIL W/HCTZ (n=27)
DANTROLENE (n=1) DISULFIRAM (n=2) (n=1)
DICLOFENAC (n=9) DRONEDARONE (n=2) CEFACLOR (n=1)
DULOXETINE (n=6) DROSPIRENONE CEFADROXIL (n=1)
ESCITALOPRAM (n=1) W/ETHINYLESTRADIOL (n=1) CEFALEXIN(n=1)
ESTRADIOL (n=1) ETODOLAC (n=2) CEFUROXIME (n=1)
ETHOSUXIMIDE (n=1) EZETIMIBE W/SIMVASTATIN DOXYCYCLINE (n=4)
FLUOXETINE (n=1) (n=2) ERYTHROMYCIN (n=2)
FLUVASTATIN (n=1) FEBUXOSTAT (n=1) FLUCONAZOLE (n=2)
HYDRALAZINE (n=4) FENOFIBRATE (n=2) GABAPENTIN (n=1)
ISONIAZID (n=32) IMATINIB (n=3) LEVOFLOXACIN (n=4)
LABETALOL (n=1) ITRACONAZOLE (n=1) LISINOPRIL (n=2)
LETROZOLE (n=1) LAMOTRIGINE (n=5) METHOTREXATE (n=1)
METHYLPHENIDATE (n=1) LANSOPRAZOLE (n=1) METHYLDOPA (n=8)
MINOCYCLINE (n=22) LAPATINIB (n=1) METOCLOPRAMIDE
NICOTINIC ACID (n=2) LEFLUNOMIDE (n=2) (n=1)
PROMETHAZINE (n=1) MELOXICAM (n=2) MOXIFLOXACIN (n=2)
PROPYLTHIOURACIL (n=2) MERCAPTOPURINE (n=5) PENICILLAMINE (n=1)
PYRAZINAMIDE (n=1) MESALAZINE (n=1) PRAVASTATIN (n=1)
QUETIAPINE (n=1) METAXALONE (n=1) RANITIDINE (n=2)
SERTRALINE (n=1) MONTELUKAST (n=2) ROSUVASTATIN (n=4)
TAMOXIFEN (n=4) NEVIRAPINE (n=2) TOPIRAMATE (n=3)
VALACICLOVIR (n=1) OLANZAPINE (n=1)
VALPROIC ACID (n=5) OXAPROZIN (n=1)
VERAPAMIL (n=3) PHENYTOIN (n=8)
PRASUGREL (n=1)
QUINAPRIL (n=1)
SIMVASTATIN (n=4)
SULFASALAZINE (n=1)
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Class 1 Class 2 Class 3 Class 4
(High solubility – Extensive
metabolism)
(n=118)
(Low solubility – Extensive
metabolism)
(n=99)
(High solubility – Poor
metabolism)
(n=115)
(Low solubility – Poor
metabolism)
(n=40)
SULFAMETHOXAZOLE
W/TRIMETHOPRIM (n=12)
TACROLIMUS (n=1)
TELITHROMYCIN (n=5)
TEMOZOLOMIDE (n=1)
TERBINAFINE (n=5)
THALIDOMIDE (n=1)
VORICONAZOLE (n=1)
Solubility refers to solubility in water: High solubility compound at the highest marketed dose strength would be soluble in 250 mL of water over
the pH range of 1–7.5 at 37°C.
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